NEWSROOM
Press releases
June 11th, 2024
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
Read the press release
March 26, 2024
Exothera pledges to fast-track RNA therapies with expansion of world-first continuous-batch RNA manufacturing solution into North America
Read the press release
![Exothera's CTO Patrick Thiaville joined Alliance of mRNA Medicine Board Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials](https://exothera.world/wp-content/uploads/2023/11/PR-AMM.png)
November 28, 2023
Exothera’s CTO Patrick Thiaville nominated as a member of Alliance for mRNA Medicines Board
Read the press release
![NIH_Press_Release_Exothera_Twitter_LinkedIn Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials](https://exothera.world/wp-content/uploads/2023/08/NIH_Press_Release_Exothera_Twitter_LinkedIn.png)
August 16, 2023
NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US
Read the press release
![Press_Release_Meissa Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials](https://exothera.world/wp-content/uploads/2023/06/Press_Release_Meissa-scaled.jpg)
June 28, 2023
Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials
Read the press release
![Press-release_Patrick_Thiaville-1.jpg Exothera Nucleic Acids Strengthens Team with Industry Expert Patrick Thiaville](https://exothera.world/wp-content/uploads/2023/05/Press-release_Patrick_Thiaville-1.jpg)
![Press-release_Remedium.jpg Remedium and Exothera partner for AAV2-FGF18](https://exothera.world/wp-content/uploads/2023/03/Press-release_Remedium.jpg)
March 22, 2023
Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18
Read the press release
![Press-release_Darren-scaled.jpg Darren Leva CBO at Exothera announced](https://exothera.world/wp-content/uploads/2023/02/Press-release_Darren-scaled.jpg)
February 1, 2023
Exothera announces the appointment of Darren Leva as Chief Business Officer
Read the press release
![Press-release_Vallo_Therapeutics.jpg Vallo Therapeutics and Exothera collaboration](https://exothera.world/wp-content/uploads/2023/01/Press-release_Vallo_Therapeutics.jpg)
January 11, 2023
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
Read the press release
![Press-release_Vaccizone-scaled.jpg Vaccizone and Exothera collaboration Sars-Cov-2](https://exothera.world/wp-content/uploads/2022/07/Press-release_Vaccizone-scaled.jpg)
July 6, 2022
Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology
Read the press release
![Press-release_PAT4CGT-1-scaled.jpg PAT4CGT initiative Exothera involved](https://exothera.world/wp-content/uploads/2022/06/Press-release_PAT4CGT-1-scaled.jpg)
June 16, 2022
PAT4CGT Consortium Announces Prestigious €4.7M Pathfinder Grant Awarded by European Innovation Council for the Development of Modular Cell & Gene Therapy Manufacturing Platform
Read the press release
![Press-release_LogicBio_Polyplus_Exothera-scaled.jpg Industrial scale AAV press release with LogicBio and Polyplus](https://exothera.world/wp-content/uploads/2022/06/Press-release_LogicBio_Polyplus_Exothera-scaled.jpg)
June 15, 2022
Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus
Read the press release
![Press-release_exoREADY-scaled.jpg press release ready-to-use viral vector production platform, exoREADY](https://exothera.world/wp-content/uploads/2022/06/Press-release_exoREADY-scaled.jpg)
June 9, 2022
Exothera develops exoREADY, a ready-to-use viral vector production platform, to accelerate advanced therapy manufacture at scale
Read the press release
![Press-release_ReiThera-scaled.jpg ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries](https://exothera.world/wp-content/uploads/2022/04/Press-release_ReiThera-scaled.jpg)
April 12, 2022
ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries
Read the press release
![Press-release_Rokote-scaled.jpg Rokote Laboratories slects Exothera for GMP manufacturing of coronavirus vaccine FINCoVac 2.0.](https://exothera.world/wp-content/uploads/2022/03/Press-release_Rokote-scaled.jpg)
March 31, 2022
Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.
Read the press release
![Press-release_GMP-scaled.jpg GMP facilities Jumet announcement](https://exothera.world/wp-content/uploads/2022/03/Press-release_GMP-scaled.jpg)
March 23, 2022
GMP certification for Exothera further expands its viral vector manufacturing capacity
Read the press release
![Press-release_IDT-scaled.jpg IDT biologika and Exothera to push forward viral vaccine scale up](https://exothera.world/wp-content/uploads/2022/03/Press-release_IDT-scaled.jpg)
March 1, 2022
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
![Press-release_Hanna_L.jpg Hanna Lesch new CTO of Exothera viral vectors](https://exothera.world/wp-content/uploads/2021/10/Press-release_Hanna_L.jpg)
October 27, 2021
Exothera announces the appointment of Hanna Lesch as Chief Technology Officer
![Press-release_GeneQuine.jpg GeneQuine and Exothera for osteoarthritis gene therapy development](https://exothera.world/wp-content/uploads/2021/09/Press-release_GeneQuine.jpg)
September 9, 2021
GeneQuine selects Exothera to support the next stage of its osteoarthritis gene therapy development
![Press-release_PALL-scaled.jpg Pall Corporation Contract With Exothera](https://exothera.world/wp-content/uploads/2021/07/Press-release_PALL-scaled.jpg)
July 1, 2021
Pall Corporation Secures Multi-Million Dollar Contract With Exothera
![Press-release_TJO.jpg Thibault Jonckheere as new CEO of Exothera](https://exothera.world/wp-content/uploads/2021/06/Press-release_TJO.jpg)
June 1, 2021
Univercells and Exothera announce Thibault Jonckheere as the new CEO of Exothera
![Press-release_Codagenix.jpg Codagenix and Univercells Collaboration High-Priority Human Vaccine Target](https://exothera.world/wp-content/uploads/2021/05/Press-release_Codagenix.jpg)
May 20, 2021
Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand
![Press-release_Cyanvac-scaled.jpg](https://exothera.world/wp-content/uploads/2021/03/Press-release_Cyanvac-1-scaled.jpg)
March 24, 2021
CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US
![Press-release_nevoline.jpg Exothera completes state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium](https://exothera.world/wp-content/uploads/2021/01/Press-release_nevoline.jpg)
January 28, 2021
Exothera completes its range of state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium
![Jumet.jpg Univercells launches cell & gene therapy CDMO Exothera with GMP capabilities](https://exothera.world/wp-content/uploads/2021/01/Jumet.jpg)